BioMed Realty Trust Reports Third Quarter 2012 Financial Results

       BioMed Realty Trust Reports Third Quarter 2012 Financial Results

Year-over-year FFO and AFFO per share rise 13.3% and 10.0%, respectively

PR Newswire

SAN DIEGO, Nov. 1, 2012

SAN DIEGO, Nov.1,2012 /PRNewswire/ --BioMed Realty Trust, Inc. (NYSE: BMR),
a real estate investment trust (REIT) that delivers optimal real estate
solutions for the life science industry, today announced financial results for
the third quarter ended September 30, 2012.

Third Quarter 2012 Highlights

  oIncreased funds from operations (FFO) for the quarter by 13.3% to $0.34
    per diluted share, as compared to $0.30 per diluted share in the third
    quarter of 2011.
  oIncreased adjusted funds from operations (AFFO) for the quarter by 10.0%
    to $0.33 per diluted share, as compared to $0.30 per diluted share in the
    third quarter of 2011.
  oIncreased the total operating portfolio leased percentage to approximately
    90.5% at quarter end, on a weighted-average basis, as the result of
    executing 22 leasing transactions during the quarter representing
    approximately 367,400 square feet, comprised of:

       o16 new leases totaling approximately 190,700 square feet, highlighted
         by a new 46,400 square foot lease with Idenix Pharmaceuticals, Inc.
         at the company's 320 Bent Street property in Cambridge,
         Massachusetts.
       oSix lease renewals totaling approximately 176,700 square feet,
         highlighted by a lease extension with a subsidiary of Vertex
         Pharmaceuticals Incorporated for approximately 81,200 square feet at
         the company's Torreyana Road property in the Torrey Pines submarket
         of San Diego, California.

  oSame property net operating income on a cash basis increased for the
    period by 7.7% and the same property leased percentage increased by 510
    basis points as compared to the same period in 2011.
  oReported net income available to common stockholders for the quarter of
    $2.8 million, or $0.02 per diluted share.
  oGenerated total revenues for the quarter of $134.5 million, up 17.4% from
    $114.6 million in the same period in 2011 and the highest in the company's
    history. Rental revenues for the quarter increased by 21.4% to $101.5
    million from $83.5 million in the same period in 2011, the highest in the
    company's history for the eleventh consecutive quarter.

Commenting on the company's third quarter results, Alan D. Gold, Chairman and
Chief Executive Officer of BioMed Realty, said, "Once again, our exceptional
operating and financial results in the third quarter were directly
attributable to sustained strong leasing success - driving over 500 basis
points of net absorption in our same property portfolio, significant cash flow
growth with a 13% increase in FFO per share and a 10% increase in AFFO per
share, and record total and rental revenues. We are proud to report that, as a
result of the third quarter leasing activity and our recently announced leases
with Regeneron Pharmaceuticals in New York and Ironwood Pharmaceuticals in
Cambridge, we have exceeded 1.8 million square feet of gross leasing volume, a
full 150% of our five-quarter leasing goal with two months remaining in the
year. This achievement demonstrates, yet again, our proven ability to
leverage BioMed Realty's particular skill, expertise and relationships in life
science real estate to create value for our stockholders."

Portfolio Update

During the quarter ended September 30,2012, the company executed 22 leasing
transactions representing approximately 367,400 square feet, comprised of 16
new leases totaling approximately 190,700 square feet and six lease renewals
totaling approximately 176,700 square feet. Leasing activity for the quarter
included a new 46,400 square foot lease with Idenix Pharmaceuticals, Inc. at
the company's 320 Bent Street property in Cambridge, Massachusetts and a lease
extension with a subsidiary of Vertex Pharmaceuticals Incorporated for
approximately 81,200 square feet at the company's Torreyana Road property in
San Diego, California. As result of the leasing volume, net absorption for the
quarter exceeded 115,000 square feet.

Same property net operating income on a cash basis increased for the period by
7.7% and the same property leased percentage increased by 510 basis points for
the quarter compared to the same period in 2011, primarily as a result of
sustained leasing success and contractual rent escalations. Operating margins
and operating expense recoveries for the third quarter increased 160 basis
points and 310 basis points, respectively, versus the same period in 2011,
driven by increased portfolio occupancy.

During the quarter, the company's largest tenant, Human Genome Sciences, Inc.,
which occupies the company's Shady Grove Road and 9911 Belward Campus Drive
properties in Rockville, Maryland and represents 10.2% of annualized base
rents, was acquired by GlaxoSmithKline plc. GlaxoSmithKline is one of the
world's leading global pharmaceutical and healthcare companies researching and
developing a broad range of innovative medicines and brands with a market
capitalization of approximately $114 billion and a credit rating of A+ from
Standard & Poor's Rating Services and A1 from Moody's Investors Service.
Primarily as a result of this transaction, the portion of BioMed Realty's
estimate of revenues attributable to global pharmaceuticals, A-rated life
science companies and their subsidiaries is approximately 25%. Approximately
83% of the company's revenues come from universities, government entities,
research institutions and public companies.

The total operating portfolio was approximately 90.5% leased on a
weighted-average basis as of September 30,2012, an increase of 360 basis
points as compared to the same period last year. Since the third quarter of
2010, the company's total operating portfolio leased percentage on a
weighted-average basis has increased 840 basis points.

Also during the quarter, the company completed the acquisition of 9900/9901
Belward Campus Drive in Rockville, Maryland for approximately $26.2 million.
The two building property comprises approximately 106,500 square feet of
laboratory and office space which is approximately 92.5% leased.

At September 30,2012, the company's total portfolio comprised approximately
13.1 million rentable square feet with an additional 4.0 million square feet
of development potential.

Subsequent to the end of the third quarter, the company signed a lease
expansion with Regeneron Pharmaceuticals, Inc. for an additional approximately
80,500 square feet at The Landmark at Eastview campus in Tarrytown, New York
and a lease expansion with Ironwood Pharmaceuticals, Inc. for approximately
93,000 square feet and an extension for the balance of the 210,000 square feet
they currently lease at the company's 301 Binney Street property in Cambridge,
Massachusetts. The term of the Ironwood lease now extends through January 31,
2018.

Third Quarter 2012 Financial Results

Total revenues for the third quarter were $134.5 million, compared to $114.6
million for the same period in 2011, an increase of 17.4% and the highest in
the company's history for the third consecutive quarter. Rental revenues for
the third quarter were $101.5 million, compared to $83.5 million for the same
period in 2011, an increase of 21.4% and the highest in the company's history
for the eleventh consecutive quarter. The company reported net income
available to common stockholders for the third quarter of $2.8 million, or
$0.02 per diluted share.

FFO was $56.2 million for the quarter, or $0.34 per diluted share, an increase
of 13.3% compared to $0.30 per diluted share for the same period in 2011.
AFFO was $55.6 million for the quarter, or $0.33 per diluted share, an
increase of 10.0% compared to $0.30 per diluted share for the same period in
2011. These amounts include other revenue of $725,000 from the early
termination of a lease with Merck at 320 Bent Street in Cambridge,
Massachusetts occurring during the quarter. Acquisition-related expenses for
the quarter were not significant.

FFO and AFFO are supplemental non-GAAP financial measures used in the real
estate industry to measure and compare the operating performance of real
estate companies. A complete reconciliation containing adjustments from GAAP
net income available to common stockholders to FFO and AFFO and definitions of
terms are included at the end of this release.

Financing Activity

During the third quarter, the company assumed two loans associated with the
acquisition of 9900/9901 Belward Campus Drive. These loans are secured by
mortgages on the two buildings with an aggregate principal balance of
approximately $24.1 million, a weighted-average interest rate of approximately
5.64% and maturity dates in July 2017.

Also during the quarter, the company amended its senior unsecured term loan
facility to convert $156.4 million of outstanding borrowings under the
facility to British pounds sterling equal to £100 million, with the base rate
index on this portion of the facility being GBP 1-month LIBOR. Concurrent
with this amendment, the company entered into interest rate swap agreements,
which were structured to have the effect of fixing interest payments on the
British pounds sterling portion outstanding under the unsecured term loan at
approximately 2.39% for the remaining term, subject to adjustment based on the
company's credit ratings.

Quarterly and Annual Distributions

BioMed Realty Trust's board of directors previously declared a third quarter
2012 dividend of $0.215 per share of common stock, and a dividend of $0.46094
per share of the company's 7.375% Series A Cumulative Redeemable Preferred
Stock for the period from July 16, 2012 through October 15, 2012. The third
quarter common share dividend is equivalent to an annualized dividend of $0.86
per common share.

Earnings Guidance

The company's revised 2012 guidance for net income per diluted share and CFFO
and FFO per diluted share is set forth and reconciled below. Projected net
income per diluted share and CFFO and FFO per diluted share are based upon
estimated, weighted-average diluted common shares outstanding of approximately
167.3 million for the full year, including the impact of the assumed
conversion of the company's exchangeable senior notes due 2030. In addition,
projected FFO and CFFO per diluted share include approximately $0.02 of
termination fee income arising from the early termination of the lease noted
above.

                                                                 2012
                                                                 (Low - High)
 Projected net income per diluted share available
 to common stockholders                $0.02
 Add:
 Impairment loss            $0.03
 Real estate depreciation and amortization      $1.21
 Noncontrolling interests in operating partnership $0.00
 Less:
 Net effect of assumed conversion of exchangeable
 senior notes due 2030 ($0.04)
 Projected FFO per diluted share               $1.22
 Acquisition-related expenses              $0.08
 Projected CFFO per diluted share             $1.30

The company's initial 2013 guidance for net income per diluted share and FFO
per diluted share are set forth and reconciled below. Projected net income per
diluted share and FFO per diluted share are based upon estimated,
weighted-average diluted common shares outstanding of approximately 168.0
million.

                                                                2013
                                                                (Low - High)
 Projected net income per diluted share available
 to common stockholders $0.15 – $0.25
 Add:
 Real estate depreciation and amortization   $1.21
 Noncontrolling interests in operating partnership $0.01
 Less:
 Net effect of assumed conversion of exchangeable
 senior notes due 2030      ($0.04)
Projected FFO per diluted share   $1.33 – $1.43

At the midpoint, the company's 2013 FFO guidance represents a 6.2% increase
over the company's 2012 core FFO guidance.

The company continues to target new investment opportunities, including
acquisitions and new development projects; however, the company's 2013 FFO
estimates do not reflect the impact of any future new investments
(acquisitions or development) as the FFO impact of such investments may vary
significantly based on the nature of these investments, timing and other
factors. In addition, these projections reflect approximately $5.8 million
($0.03 per diluted share) in other revenue related to Merck's 2012 lease
termination.

The foregoing estimates are forward-looking and reflect management's view of
current and future market conditions, including certain assumptions with
respect to leasing activity, rental rates, occupancy levels, interest rates,
financings, acquisitions, development and redevelopment and the amount and
timing of acquisitions, development and redevelopment activities. The
company's actual results may differ materially from these estimates.

Supplemental Information

Supplemental operating and financial data are available in the Investor
Relations section of the company's website at www.biomedrealty.com.

Teleconference and Webcast

BioMed Realty will conduct a conference call and webcast at 10:00 a.m. Pacific
Time (1:00 p.m. Eastern Time) on Friday, November 2, 2012 to discuss the
company's financial results and operations for the quarter. The call will be
open to all interested investors either through a live audio web cast at the
Investor Relations section of the company's web site at
www.biomedrealty.comand at www.earnings.com, which will include an online
slide presentation to accompany the call, or live by calling (866) 638-3013
(domestic) or (630) 691-2761 (international) with call ID number 33615224. The
complete webcast will be archived for 30 days on both web sites. A telephone
playback of the conference call will also be available from 12:30 p.m. Pacific
Time on Friday, November 2, 2012 until midnight Pacific Time on Wednesday,
November 7, 2012 by calling (888) 843-7419 (domestic) or (630) 652-3042
(international) and using access code 33615224#.

About BioMed Realty Trust

BioMed Realty delivers optimal real estate solutions for biotechnology and
pharmaceutical companies, scientific research institutions, government
agencies and other entities involved in the life science industry. BioMed
Realty owns or has interests in properties comprising approximately 13.1
million rentable square feet. The company's properties are located
predominantly in the major U.S. life science markets of Boston, San Francisco,
San Diego, Maryland, New York/New Jersey, Pennsylvania and Seattle, which have
well-established reputations as centers for scientific research. Additional
information is available at www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These risks
and uncertainties include, without limitation: general risks affecting the
real estate industry (including, without limitation, the inability to enter
into or renew leases, dependence on tenants' financial condition, and
competition from other developers, owners and operators of real estate);
adverse economic or real estate developments in the life science industry or
the company's target markets; risks associated with the availability and terms
of financing, the use of debt to fund acquisitions, developments and other
investments, and the ability to refinance indebtedness as it comes due;
failure to maintain the company's investment grade credit ratings with the
ratings agencies; failure to manage effectively the company's growth and
expansion into new markets, or to complete or integrate acquisitions and
developments successfully; reductions in asset valuations and related
impairment charges; risks and uncertainties affecting property development and
construction; risks associated with downturns in foreign, domestic and local
economies, changes in interest rates and foreign currency exchange rates, and
volatility in the securities markets; ownership of properties outside of the
United States that subject the company to different and potentially greater
risks than those associated with the company's domestic operations; risks
associated with the company's investments in loans, including borrower
defaults and potential principal losses; potential liability for uninsured
losses and environmental contamination; risks associated with the company's
potential failure to qualify as a REIT under the Internal Revenue Code of
1986, as amended, and possible adverse changes in tax and environmental laws;
and risks associated with the company's dependence on key personnel whose
continued service is not guaranteed. For a further list and description of
such risks and uncertainties, see the reports filed by the company with the
Securities and Exchange Commission, including the company's most recent annual
report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

(Financial Tables Follow)

BIOMED REALTY TRUST, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)
                                                   September 30,  December 31,

                                                   2012           2011
                                                   (Unaudited)
ASSETS
Investments in real estate, net                    $  4,327,426   $ 3,950,246
Investments in unconsolidated partnerships         31,955         33,389
Cash and cash equivalents                          20,646         16,411
Accounts receivable, net                           7,128          5,141
Accrued straight-line rents, net                   144,975        130,582
Deferred leasing costs, net                        180,925        157,255
Other assets                                       118,052        135,521
Total assets                                       $  4,831,107   $ 4,428,545
LIABILITIES AND EQUITY
Mortgage notes payable, net                        $  574,497     $ 587,844
Exchangeable senior notes                          180,000        180,000
Unsecured senior notes, net                        893,955        645,581
Unsecured senior term loan                         405,216        -
Unsecured line of credit                           87,000         268,000
Accounts payable, accrued expenses and other       178,706        134,924
liabilities
Total liabilities                                  2,319,374      1,816,349
Equity:
Stockholders' equity:
Preferred stock, $.01 par value, 15,000,000 shares
authorized: 7.375% Series Acumulative redeemable
preferred stock, $198,000 liquidation              191,469        191,469
preference($25.00 per share), 7,920,000 shares
issued and outstanding at September 30, 2012
andDecember 31, 2011
Common stock, $.01 par value, 200,000,000 shares
authorized, 154,334,988 and154,101,482 shares     1,543          1,541
issued and outstanding at September 30, 2012 and
December 31, 2011, respectively
Additional paid-in capital                         2,779,035      2,773,994
Accumulated other comprehensive loss, net          (56,988)       (60,138)
Dividends in excess of earnings                    (411,529)      (304,759)
Total stockholders' equity                         2,503,530      2,602,107
Noncontrolling interests                           8,203          10,089
Total equity                                       2,511,733      2,612,196
Total liabilities and equity                       $  4,831,107   $ 4,428,545



BIOMED REALTY TRUST, INC.


CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share data)

(Unaudited)
                    For the Three Months Ended    For the Nine Months Ended
                    September 30,                 September 30,
                    2012           2011           2012            2011
Revenues:
Rental              $  101,467     $  83,549      $ 288,650       $   244,598
Tenant recoveries   31,765         26,603           89,155        75,867
Other revenue       1,305          4,487            1,590         5,775
                                                    
Total revenues      134,537        114,639                        326,240
                                                    379,395
Expenses:
Rental operations   38,944         33,876        112,717          96,246
Depreciation and    51,372         36,203        143,882          105,649
amortization
General and         10,226         7,682         27,416           21,797
administrative
Acquisition-related 176            136               13,055       789
expenses
Total expenses      100,718        77,897            297,070      224,481
Income from         33,819         36,742        82,325           101,759
operations
Equity in net loss
of unconsolidated   (339)          (735)         (1,011)          (1,849)
partnerships
Interest expense,   (26,817)       (22,887)      (72,863)         (67,456)
net
Other expense       (208)          (4,259)           (580)        (6,005)
Income from
continuing          6,455          8,861         7,871            26,449
operations
 Income / (loss) 
from discontinued                  76                (4,370)      312
operations          —
 Net income      6,455          8,937         3,501            26,761
Net (income) / loss
attributable to     (46)           (106)             156          (281)
noncontrolling
interests
Net income
attributable to the 6,409          8,831         3,657            26,480
company
Preferred stock     (3,651)        (3,901)       (10,952)         (12,382)
dividends
Cost on redemption  —              (165)          —               (165)
of preferred stock
Net income / (loss)
available to common $  2,758       $  4,765       $ (7,295)       $   13,933
stockholders
Income / (loss)
from continuing
operations per
share available to
common
stockholders:
Basic and diluted   $  0.02        $  0.03        $ (0.02)        $   0.10
earnings per share
Income / (loss)
from discontinued
operations per
share

available to common
stockholders:
Basic and diluted   $  —           $  —           $ (0.03)        $   —
earnings per share
Net income / (loss)
per share available
to common
stockholders:
Basic and diluted   $  0.02        $  0.03        $ (0.05)        $   0.10
earnings per share
Weighted-average
common shares
outstanding:
Basic               152,785,451    129,872,349       152,739,130  129,834,429
Diluted             155,728,209    132,852,328       152,739,130  132,819,688



BIOMED REALTY TRUST, INC.

CONSOLIDATED FUNDS FROM OPERATIONS

(In thousands, except share data)

(Unaudited)


Our FFO and CFFO available to common shares and partnership and LTIP units
and a reconciliation to net income for the three and nine months ended
September 30, 2012 and 2011 was as follows:
                       Three Months Ended          Nine Months Ended
                       September 30,               September 30,
                       2012          2011          2012             2011
Net income / (loss)
available to the       $   2,758     $   4,765     $  (7,295)    $  13,933
common stockholders
Adjustments:
Impairment loss        —             —             4,552         —
Noncontrolling
interests in operating 53            111           (140)         318
partnership
Depreciation and
amortization –         323           945           968           2,810
unconsolidated
partnerships
Depreciation and
amortization –         51,372        36,203        143,882       105,649
consolidated entities
Depreciation and
amortization –         —             92            92            270
discontinued
operations
Depreciation and
amortization –
allocable to
noncontrolling         (28)          (26)          (83)          (77)
interest of
consolidated joint
ventures
FFO available to
common shares and      $   54,478    $   42,090    $  141,976    $  122,903
units – basic
 Interest expense
on exchangeable senior     1,688         1,688        5,063         5,063
notes
FFO available to
common shares and      $   56,166    $   43,778    $  147,039    $  127,966
units – diluted

Acquisition-related        176           136          13,055        789
expenses
CFFO – diluted         $   56,342        43,914    $  160,094    $  128,755
FFO per share –        $   0.34      $   0.30      $  0.88       $  0.89
diluted
CFFO per share –       $   0.34      $   0.30      $  0.96       $  0.89
diluted
Weighted-average
common shares and      167,350,914   144,260,059   167,275,526   144,261,742
units outstanding –
diluted (1)

Our AFFO available to common shares and partnership and LTIP units and a
reconciliation of CFFO to AFFO for the three and nine months ended
September30,2012 and 2011 was as follows:

                        Three Months Ended          Nine Months Ended
                        September 30,               September 30,
                        2012          2011          2012          2011
CFFO - diluted          $   56,342       43,914     $  160,094    $  128,755
Adjustments:
Recurring capital
expenditures and second (2,739)       (4,114)       (8,800)       (10,679)
generation tenant
improvements
Leasing commissions     (2,001)       (1,096)       (4,755)       (3,125)
Non-cash revenue        (2,590)       (5,080)       (3,994)       (10,041)
adjustments
Non-cash debt           3,026         6,619         9,080         12,774
adjustments
Non-cash equity         3,094         1,898         8,670         5,554
compensation
Cost on redemption of   —             165           —             165
preferred stock
Depreciation included
in general and          483           435           1,380         1,213
administrative expenses
Share of non-cash
unconsolidated          26            (58)          53            (25)
partnership adjustments
AFFO available to       $   55,641       42,683     $  161,728    $  124,591
common shares and units
AFFO per share –        $   0.33         0.30       $  0.96       $  0.87
diluted
Weighted-average common
shares and units
outstanding -           167,350,914   144,260,059   167,275,526   144,261,742

diluted (1)
        The three and nine months ended September 30, 2012 include 10,127,232
        shares of common stock potentially issuable pursuant to the exchange
        feature of the exchangeable senior notes due 2030 based on the "if
        converted" method. The three and nine months ended September 30, 2011
        include 10,017,858 shares of common stock potentially issuable
        pursuant to the exchange feature of the exchangeable senior notes due
        2030 based on the "if converted" method. The nine months ended
(1)     September 30, 2012 includes 2,951,914 shares of OP and LTIP units,
        which are considered anti-dilutive for purposes of calculating diluted
        earnings per share. The three months ended September 30, 2012 and 2011
        include 1,495,473 and 1,389,873 shares of unvested restricted stock,
        respectively, which are considered anti-dilutive for purposes of
        calculating diluted earnings per share. The nine months ended
        September 30, 2012 and 2011 include 1,457,250 and 1,424,196 shares of
        unvested restricted stock, respectively, which are considered
        anti-dilutive for purposes of calculating diluted earnings per share.

We present funds from operations, or FFO, core funds from operations, or CFFO,
and adjusted funds from operations, or AFFO, available to common shares and
partnership and LTIP units because we consider them important supplemental
measures of our operating performance and believe they are frequently used by
securities analysts, investors and other interested parties in the evaluation
of REITs, many of which present FFO, CFFO and AFFO when reporting their
results.

FFO is intended to exclude GAAP historical cost depreciation and amortization
of real estate and related assets, which assumes that the value of real estate
assets diminishes ratably over time. Historically, however, real estate values
have risen or fallen with market conditions. Because FFO excludes depreciation
and amortization unique to real estate, gains and losses from property
dispositions and extraordinary items, it provides a performance measure that,
when compared year over year, reflects the impact to operations from trends in
occupancy rates, rental rates, operating costs, development activities and
interest costs, providing perspective not immediately apparent from net
income. We compute FFO in accordance with standards established by the Board
of Governors of the National Association of Real Estate Investment Trusts, or
NAREIT. As defined by NAREIT, FFO represents net income (computed in
accordance with GAAP), excluding gains (or losses) from sales of property,
impairment charges on depreciable real estate, real estate related
depreciation and amortization (excluding amortization of loan origination
costs) and after adjustments for unconsolidated partnerships and joint
ventures.

We calculate CFFO by adding acquisition-related expenses to FFO. We calculate
AFFO by adding to CFFO: (a) non-cash revenues and expenses, (b) recurring
capital expenditures and second generation tenant improvements, and (c)
leasing commissions.

Our computation of FFO, CFFO and AFFO may differ from the methodology for
calculating FFO, CFFO and AFFO utilized by other equity REITs and,
accordingly, may not be comparable to such other REITs. Further, FFO, CFFO and
AFFO do not represent cash flow available for management's discretionary use
because of needed capital replacement or expansion, debt service obligations,
or other commitments and uncertainties. FFO, CFFO and AFFO should not be
considered as an alternative to net income (loss) (computed in accordance with
GAAP) as an indicator of our financial performance or to cash flow from
operating activities (computed in accordance with GAAP) as an indicator of our
liquidity, nor is it indicative of funds available to fund our cash needs,
including our ability to pay dividends or make distributions. FFO, CFFO and
AFFO should be considered only as supplements to net income computed in
accordance with GAAP as measures of our operations.

SOURCE BioMed Realty Trust, Inc.

Website: http://www.biomedrealty.com
Contact: Rick Howe, Senior Director, Corporate Communications, 858.207.5859,
richard.howe@biomedrealty.com